Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28059266 | 0.90 | EGFR (0.77) | BTKEGFR | |
| SCHEMBL9945480 | 0.88 | BTK (0.69) | BTKEGFR | |
| SCHEMBL15814594 | 0.88 | EGFR (0.74) | BTKEGFR | |
| SCHEMBL9923766 | 0.88 | BTK (0.74) | BTKEGFR | |
| SCHEMBL28980994 | 0.85 | MAPK3 (0.54) | BTKEGFR | |
| SCHEMBL31684794 | 0.85 | MAPK3 (0.54) | BTKEGFR | |
| SCHEMBL16370843 | 0.85 | EGFR (0.73) | BTKEGFR | |
| SCHEMBL9924738 | 0.85 | BTK (0.69) | BTKEGFR | |
| SCHEMBL15974304 | 0.84 | EGFR (0.62) | BTKEGFR | |
| SCHEMBL28782963 | 0.84 | CTSL (0.57) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218704-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2022-07-14 | — | — | US | disclosed |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2020-09-03 | — | — | US | disclosed |
| CN-105384695-B | Pyrimidine derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-10-08 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-9375431-B2 | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375431-B2 | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| CN-105384695-A | Pyrimidine derivative, preparation method therefor and application thereof in medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-03-09 | — | — | CN | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434101-B2 | Heterocyclic compounds and uses thereof | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885 |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885 |
| US-20220218704-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885 |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885 |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885 |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.